372 related articles for article (PubMed ID: 6786828)
1. Correlation between the serum norethindrone (NET) levels attained after insertion of a silastic implant releasing norethindrone acetate and the endogenous hormones particularly progesterone.
Laumas V; Jain AK; Jha P; Rahman SA; Kumar D; Malik BK; Sarkar NN; Takkar D; Hingorani V; Laumas KR
Contraception; 1981 Feb; 23(2):211-25. PubMed ID: 6786828
[TBL] [Abstract][Full Text] [Related]
2. Effect of norethindrone acetate released from a single silastic implant on serum FSH, LH, progesterone and estradiol-17beta of women during first eight months of treatment.
Rahman SA; Jha P; Laumas V; Jain AK; Dileepkumar ; Takkar D; Hingorani V; Laumas KR
Contraception; 1977 Nov; 16(5):487-97. PubMed ID: 590011
[TBL] [Abstract][Full Text] [Related]
3. Serum norethindrone (NET) concentrations following intramuscular NET enanthate injection. Effect upon serum LH, FSH, estradiol and progesterone.
Goebelsmann U; Stanczyk FZ; Brenner PF; Goebelsmann AE; Gentzschein EK; Mishell DR
Contraception; 1979 Mar; 19(3):283-313. PubMed ID: 572279
[TBL] [Abstract][Full Text] [Related]
4. Hormonal effects of the 300 microgram norethisterone (NET) minipill. 3. Comparison of the short-term (2nd month) and medium-term (6th month) effects in 21 subjects.
Landgren BM; Lager S; Diczfalusy E
Contraception; 1981 Mar; 23(3):269-99. PubMed ID: 6786830
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of ovulation by progestin analogs (agonists vs antagonists): preliminary evidence for different sites and mechanisms of actions.
Heikinheimo O; Gordon K; Williams RF; Hodgen GD
Contraception; 1996 Jan; 53(1):55-64. PubMed ID: 8631191
[TBL] [Abstract][Full Text] [Related]
6. Comparative studies of the ethynyl estrogens used in oral contraceptives. III. Effect on plasma gonadotropins.
Goldzieher JW; de la Peña A; Chenault CB; Cervantes A
Am J Obstet Gynecol; 1975 Jul; 122(5):625-36. PubMed ID: 1146928
[TBL] [Abstract][Full Text] [Related]
7. Interference with ovulation by sequential treatment with the antiprogesterone RU486 and synthetic progestin.
Kekkonen R; Alfthan H; Haukkamaa M; Heikinheimo O; Luukkainen T; Lähteenmäki P
Fertil Steril; 1990 Apr; 53(4):747-50. PubMed ID: 2108063
[TBL] [Abstract][Full Text] [Related]
8. Serum levels of FSH, LH, estradiol-17 beta and progesterone following the administration of a combined oral contraceptive containing 20 micrograms ethinylestradiol.
Carlström K; Lunell NO; Zador G
Gynecol Obstet Invest; 1978; 9(6):304-11. PubMed ID: 754992
[TBL] [Abstract][Full Text] [Related]
9. A regimen of oral contraceptives restricted to the periovulatory period may permit folliculogenesis but inhibit ovulation.
Letterie GS
Contraception; 1998 Jan; 57(1):39-44. PubMed ID: 9554249
[TBL] [Abstract][Full Text] [Related]
10. A comparative study of two contraceptive vaginal rings releasing norethindrone acetate and differing doses of ethinyl estradiol.
Weisberg E; Fraser IS; Mishell DR; Lacarra M; Darney P; Jackanicz TM
Contraception; 1999 May; 59(5):305-10. PubMed ID: 10494484
[TBL] [Abstract][Full Text] [Related]
11. LH, FSH, estradiol and progesterone levels after discontinuation of hormonal contraception.
Balogh A; Ditrói F; Lampé LG
Acta Univ Palacki Olomuc Fac Med; 1981; 101():95-101. PubMed ID: 6242699
[TBL] [Abstract][Full Text] [Related]
12. Effect of levonorgestrel-releasing intrauterine device on hormonal profile and menstrual pattern after long-term use.
Xiao B; Zeng T; Wu S; Sun H; Xiao N
Contraception; 1995 Jun; 51(6):359-65. PubMed ID: 7554977
[TBL] [Abstract][Full Text] [Related]
13. Sequential regimen of the antiprogesterone RU486 and synthetic progestin for contraception.
Kekkonen R; Lähteenmäki P; Luukkainen T; Tuominen J
Fertil Steril; 1993 Oct; 60(4):610-5. PubMed ID: 8405512
[TBL] [Abstract][Full Text] [Related]
14. Plasma levels of adrenocorticotropin and cortisol in women receiving oral contraceptive steroid treatment.
Carr BR; Parker CR; Madden JD; MacDonald PC; Porter JC
J Clin Endocrinol Metab; 1979 Sep; 49(3):346-9. PubMed ID: 224073
[TBL] [Abstract][Full Text] [Related]
15. Levels of follicle-stimulating hormone, luteinizing hormone, oestradiol-17 beta and progesterone, and follicular growth in the pseudopregnant rat.
Welschen R; Osman P; Dullaart J; de Greef WJ; Uilenbroek JT; de Jong FH
J Endocrinol; 1975 Jan; 64(1):37-47. PubMed ID: 1167896
[TBL] [Abstract][Full Text] [Related]
16. Sonographic assessment of ovarian and endometrial changes during long-term Norplant use and their correlation with hormonal levels.
Shaaban MM; Segal S; Salem HT; Ghaneimah SA; Khalifa EA; Ahmed AG
Fertil Steril; 1993 May; 59(5):998-1002. PubMed ID: 8486202
[TBL] [Abstract][Full Text] [Related]
17. The effect of a synthetic progestogen, ethylnorgestrienone, on hypothalamic-pituitary-ovarian function, cervical mucus, vaginal cytology, and endometrial morphology.
Niaraki MA; Moghissi KS; Borin K
Fertil Steril; 1981 Mar; 35(3):284-8. PubMed ID: 6781938
[TBL] [Abstract][Full Text] [Related]
18. The effect of monophasic combinations of ethinyl estradiol and norethindrone on gonadotropins, androgens and sex hormone binding globulin: a randomized trial.
Moutos D; Smith S; Zacur H
Contraception; 1995 Aug; 52(2):105-9. PubMed ID: 8536446
[TBL] [Abstract][Full Text] [Related]
19. Effects of low dose oral contraceptives containing norethindrome and ethinyl estradiol on serum levels of progesterone and pituitary gonadotropins.
McGuire JL; Bariso CD; Yuliano E; Hume RJ; Pasquale SA
Contraception; 1975 Mar; 11(3):329-38. PubMed ID: 1116369
[TBL] [Abstract][Full Text] [Related]
20. The effect of norethisterone (500 mcg) and ethinyl estradiol (35 mcg) capsules on the pituitary-ovarian axis.
Nuttall ID; Elstein M; Fahmy DR
Contraception; 1982 May; 25(5):463-9. PubMed ID: 6809424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]